Concepedia

Emre Altinmakas

EA

Statistics

Publications

5

Citations

471

H-Index

5

Active since

2014

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Harvard University

Dana-Farber Cancer Institute

Beth Israel Deaconess Medical Center

Emre Altinmakas is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and urology.

ORCID

Top concepts

Publications per year

2014–2020

5

Publications

5

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir, Eric Jonasch, Laurence Albigès et al. · European Urology · 2015 · 356 citations · Full text

, , +4

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

Matthew T. Campbell, Mehmet Asım Bilen, Amishi Y. Shah et al. · European Journal of Cancer · 2018 · 64 citations

, , +5

Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.

Nizar M. Tannir, Eric Jonasch, Emre Altinmakas et al. · Journal of Clinical Oncology · 2014 · 26 citations

, , +14

Clinical Importance of Incidental Homogeneous Renal Masses That Measure 10–40 mm and 21–39 HU at Portal Venous Phase CT: A 12-Institution Retrospective Cohort Study

Michael T. Corwin, Emre Altinmakas, Daniella Asch et al. · American Journal of Roentgenology · 2020 · 14 citations

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Matthew T. Campbell, Randall E. Millikan, Emre Altinmakas et al. · Clinical Genitourinary Cancer · 2014 · 11 citations · Full text

, , +4

1–5 of 5